{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:27:42Z","timestamp":1785864462606,"version":"3.56.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jpba.2019.04.035","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T11:42:08Z","timestamp":1555414928000},"page":"278-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities"],"prefix":"10.1016","volume":"172","author":[{"given":"Oliver","family":"Scherf-Clavel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kinzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Besa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Bidmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Abdel-Tawab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Wohlfart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"S\u00f6rgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Holzgrabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.04.035_bib0005","series-title":"Valsartan: Charchenbezogener R\u00fcckruf valsartanhaltiger Arzneimittel, deren Wirkstoff von dem chinesischen Hersteller Zhejiang Huahai Pharmaceutical produziert wurde. Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte","year":"2019"},{"key":"10.1016\/j.jpba.2019.04.035_bib0010","first-page":"1","article-title":"Noch mehr nitrosamine","volume":"1-2","author":"Buschmann","year":"2019","journal-title":"DAZ"},{"key":"10.1016\/j.jpba.2019.04.035_bib0015","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3762\/bjoc.11.187","article-title":"Dimethylamine as the key intermediate generated in situ from dimethylformamide (DMF) for the synthesis of thioamides","volume":"11","author":"Liu","year":"2015","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.jpba.2019.04.035_bib0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-4274(97)00048-9","article-title":"On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome","volume":"92","author":"Williamson","year":"1997","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.jpba.2019.04.035_bib0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199008093230601","article-title":"An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use","volume":"323","author":"Belongia","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2019.04.035_bib0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/mrc.1222","article-title":"Assignment of the major and minor components of gentamicin for evaluation of batches","volume":"41","author":"Deubner","year":"2003","journal-title":"Magn. Reson. Chem."},{"key":"10.1016\/j.jpba.2019.04.035_bib0035","doi-asserted-by":"crossref","DOI":"10.1001\/jama.282.10.932-JFD90007-2-1","article-title":"Endotoxin-like reactions to gentamicin sulfate","volume":"282","author":"Henney","year":"1999","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jpba.2019.04.035_bib0040","series-title":"Impurities in New Drug Products","year":"2006"},{"key":"10.1016\/j.jpba.2019.04.035_bib0045","series-title":"Assessment and Control of DNA Reactive (mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7(R1)","year":"2017"},{"key":"10.1016\/j.jpba.2019.04.035_bib0050","series-title":"FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan","year":"2019"},{"key":"10.1016\/j.jpba.2019.04.035_bib0055","doi-asserted-by":"crossref","first-page":"10559","DOI":"10.1021\/acs.analchem.8b02679","article-title":"A novel impurity-profiling workflow with the combination of flash-chromatography, UHPLC-MS, and multivariate data analysis for highly pure drugs: a study on the synthetic cannabinoid MDMB-CHMICA","volume":"90","author":"Munster-Muller","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2019.04.035_bib0060","article-title":"High resolution mass spectrometry for structural elucidation and quantitation of drugs and their metabolites based on multiple MS and MS\/MS workflows","author":"T. D. Hopfgartner","year":"2011","journal-title":"Proceedings of the 59th ASMS Conference on Mass Spectrometry and Allied Topics"},{"key":"10.1016\/j.jpba.2019.04.035_bib0065","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s00216-011-5641-8","article-title":"High-resolution mass spectrometry for integrated qualitative and quantitative analysis of pharmaceuticals in biological matrices","volume":"402","author":"Hopfgartner","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2019.04.035_bib0070","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/ed100697w","article-title":"ChemSpider: an online chemical information resource","volume":"87","author":"Pence","year":"2010","journal-title":"J. Chem. Educ."},{"key":"10.1016\/j.jpba.2019.04.035_bib0075","series-title":"Process for Preparing Irbesartan","author":"Reguri","year":"2005"},{"key":"10.1016\/j.jpba.2019.04.035_bib0080","series-title":"Improved Method for Preparing Tetrazole for Valsartan","author":"Zhu","year":"2004"},{"key":"10.1016\/j.jpba.2019.04.035_bib0085","doi-asserted-by":"crossref","first-page":"8084","DOI":"10.1021\/jo9824910","article-title":"Novel syntheses of 2-Butyl-5-chloro-3H-imidazole-4-carbaldehyde: a key intermediate for the synthesis of the angiotensin II antagonist losartan","volume":"64","author":"Griffiths","year":"1999","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.jpba.2019.04.035_bib0090","series-title":"Preparation of Pharmaceutical Intermediate 2-N-butyl-4(5)-Chloro-5-(4)-Formaldehyde-1H-Imidazole","author":"Zhang","year":"2015"},{"key":"10.1016\/j.jpba.2019.04.035_bib0095","series-title":"Method for Preparing 2-N-Butyl-4-Chloro-5-Formylimidazole","author":"Zhang","year":"2017"},{"key":"10.1016\/j.jpba.2019.04.035_bib0100","series-title":"NTP. N,N-Dimethylvaleramide (6225-06-5). Chemical Effects in Biological Systems (CEBS)","year":"2019"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519301864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519301864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:57:19Z","timestamp":1760000239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519301864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":20,"alternative-id":["S0731708519301864"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.04.035","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.04.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.05.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}